Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1355-1361

  Ueda, Hiroki ^a   Tanaka, Hiroto ^a   Kida, Yohei ^a   Fukuchi, Hiroko ^a   Ichinose, Masakazu ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Hepatocellular carcinoma; Tegafur; Transcatheter arterial chemoembolization; Uracil

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; UFT; VASCULOTROPIN; TEGAFUR; URACIL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; STOMATITIS; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NECROSIS; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; PROPORTIONAL HAZARDS MODELS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 47549118684     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1355     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay I and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. El-Assal ON, Yamanoi A, Soda Y, et al: Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27: 1554-1562, 1998.
3. Miura H, Miyazaki T, Kuroda M, et al: Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 27: 854-861, 1997.
4. Mise M, Arii S, Higashituji H, et al: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23: 455-464, 1996.
5. Torimura T, Sata M, Ueno T, et al: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29: 986-991, 1998.
6. Li XM, Tang ZY, Zhou G, Lui YK and Ye SL: Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17: 13-17, 1998.
7. Yamaguchi R, Yano H, Iemura A, Ogasawa S, Haramaki M and Kojiro M: Expression of vascular endothelial growth factor in human hepatocellualr carcinoma. Hepatology 28: 68-77, 1998.
8. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and Wong J: Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9: 5339-5345, 2003.
9. Schmitt M, Horbach A, Kubitz R, Frilling A and Haussinger D: Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 41: 274-283, 2004.
10. Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S and Ishii H: Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol 14: 1087-1090, 1999.
11. Hamada C, Tanaka F, Ohta M, et al: Meta-analysis of post-operative adjuvant chemotherapy with Tegafur-Uracil in non-small-cell lung cancer. J Clin Oncol 23: 4999-5006, 2005.
12. Noguchi S, Koyama H, Uchino J, et al: Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol 23: 2172-2184, 2005.
13. Sakamoto J, Hamada C, Yoshida S, et al: An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 96: 1170-1177, 2007.
14. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004.
15. Yonekura K, Basaki Y, Chikahisa L, et al: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5: 2185-2191, 1999.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
17. Japanese Liver Cancer Study Group of Japan: Criteria for the evaluation of direct effects of hepatocellular carcinoma. ACTA Hepatol Jpn 45: 380-385, 2004.
18. Arimura E, Kotoh K, Nakamuta M, Morizono S, Enjoji M and Nawata H: Local recurrence is an important prognostic factor of hepatocellular carcinoma. World J Gastroenterol 11: 5601-5606, 2005.
19. Takayasu K, Arii S, Ikai I, et al: Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemo-embolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469, 2006.
20. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359: 1734-1739, 2002.
21. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
22. Wakasa K, Sakurai M, Kuroda C, Marukawa T, Monden M, Okamura J and Kurata A: Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer 65: 913-919, 1990.
23. Ikeda K, Kumada H, Saitoh S, Arase Y and Chayama K: Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 68: 2150-2154, 1991.
24. Muto Y, Moriwaki H, Ninomiya M, et al: Prevention of second primary tumors by an acycric retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Eng J Med 334: 1561-1567, 1996.
25. Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134: 963-967, 2001.
26. Shiratori Y, Shiina S, Teratani T, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138: 299-306, 2003.
27. Yamamoto M, Arii S, Sugahara K and Tobe T: Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83: 336-340, 1996.
28. Ishikawa T, Ichida T, Ishimoto Y, et al: Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. Am J Gastroenterol 94: 1682-1685, 1999.
29. Ishikawa T, Ichida T, Sugitani S, et al: Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV - A hepatocellular carcinoma. J Gastroenterol Hepatol 16: 452-459, 2001.
30. Basaki Y, Chikahisa L, Aoyagi K, et al: Gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 4: 163-173, 2001.
31. Hasegawa K, Takayama T, Ijichi M, et al: Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 44: 891-895, 2006.
32. Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K and Kumada HA: A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 18: 204-210, 1995.
33. Doyon DMA, Jourde AM, Regensberg C and Frileux C: L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol 17: 593-603, 1974.
34. Yamada R, Nakatsuka H, Nakamura K, et al: Transcatheter arterial embolization therapy in unresectable hepatomas - experience in 15 cases. ACTA Hepatol Jpn 20: 595-603, 1979.
35. Liao XF, Yi JL, Li XR, Deng W, Yang ZF and Tian G: Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 10: 1885-1889, 2004.